Medi-Exametazim

Exametazime, the active ingredient in Medi-Exametazim, is a radiopharmaceutical presented as a sterile injectable solution for intravenous use. It is employed to label white blood cells for imaging infection and inflammation in patients undergoing diagnostic evaluation. GNH USA supplies Medi-Exametazim as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Medi-Exametazim is used in nuclear medicine to visualize sites of infection and inflammation through leukocyte labeling. - Infection detection: enables visualization of bacterial infection sites using radiolabeled white blood cells. - Osteomyelitis imaging: assists in locating bone infection and assessing treatment response. - Fever of unknown origin: helps identify occult infectious foci when conventional tests are inconclusive. - Inflammatory disease imaging: highlights active inflammatory lesions in conditions such as vasculitis or sarcoidosis.

Adverse reactions may occur following intravenous administration of Exametazime‑labeled leukocytes. Common Side Effects: - Nausea: mild, transient feeling of stomach upset. - Headache: occasional mild to moderate intensity. - Injection site pain: brief discomfort at the infusion site. - Flushing: transient warmth or redness of the skin. Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Severe hypotension: marked drop in blood pressure that may cause dizziness or fainting. - Pulmonary embolism: rare clot formation in the lungs associated with radiolabeled cell aggregates.

Use of Medi-Exametazim requires careful assessment of patient-specific factors and handling requirements. - Pregnancy: safety not established; avoid unless benefits outweigh potential risks. - Breastfeeding: unknown excretion in milk; consider discontinuation of nursing. - Renal impairment: monitor as altered clearance may affect image quality. - Concurrent immunosuppressive therapy: may reduce leukocyte labeling efficiency. - Known hypersensitivity to radiopharmaceutical components: assess risk before administration. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Exametazime may interact with other agents that affect leukocyte function or radiation exposure. Major Interactions (Avoid): - Concurrent radiolabeled leukocyte agents: may cause overlapping radiation dose. - High‑dose corticosteroids: can suppress leukocyte labeling and reduce imaging sensitivity. - Chemotherapeutic drugs causing leukopenia: diminish available leukocytes for labeling. Moderate Interactions (Monitor Closely): - Anticoagulants: may alter vascular imaging interpretation. - Beta‑blockers: could mask cardiovascular side effects of the radiotracer.